PharmaBiome is a privately-held spin-off company of ETH Zurich and has developed the first-in-the-industry, patent-protected technology platform for the production of standardized microbiome-based products. The company's goal is to create personalized treatments for patients with chronic inflammatory diseases, immune conditions, and special nutritional needs by using a biology-based analysis tool to identify and select the metabolic functions needed to restore the gut microbiome to a balanced state. The resulting formulation compounds over 500 different strains of bacteria into a minimal consortium of bacteria representing a healthy microbiome, which is then transformed into a live biotherapeutic product. The speed and flexibility of this process give PharmaBiome a unique advantage in bringing effective treatment options to market.